Abstract
BackgroundMUM-LM are resistant to ICIs for several reasons including the prevalence of myeloid-derived suppressor cells (MDSCs). PFS has been limited, even with approved therapies such as tebentafusp (median 3.3 months)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have